North America Antinuclear Antibody Test Market

North America Antinuclear Antibody Test Market Size & Growth (2022 to 2027):

As per the research report, the size of the North America Antinuclear Antibody Test Market is valued at USD 443.19 million in 2022 and expected to reach USD 784.54 million by 2027 at a CAGR of 12.10% during the forecast period 2022 to 2027.

Increased frequency of autoimmune disorders such as rheumatoid arthritis and SLE and public awareness of these diseases are driving the antinuclear antibody test market in North America.

Autoimmune diseases can result in type 1 diabetes. As a result, the number of persons with diabetes increased from 108 million to 422 million between 1980 and 2014, according to the WHO. Other drivers propelling the market in North America include an increase in people's healthcare spending as a result of developing economies and government healthcare insurance and reimbursement laws.

Antinuclear antibody testing is becoming more popular for SLE and other autoimmune diseases, and it is expected to grow in the future. The function of the primary healthcare physician's delivery system is to boost the need for ANA. Autoimmune illnesses such as lupus erythematosus and rheumatoid arthritis are becoming more common, driving increased market demand. Government initiatives for early diagnosis and increased research and development activities in autoimmune illnesses are also likely to boost market demand. The ANA tests are pretty precise. As a result, it contributes to the growth of the antinuclear antibody test market in North America. 

Factors like this contribute to the North America Antinuclear Antibody Test market during the forecasted period.

Diagnostic errors, product approval issues, and a scarcity of trained labor impede the antinuclear antibody test market's growth in North America.

Furthermore, the cost of these tests is less prohibitively expensive for patients, which could limit sales in the North American market. The market growth is hampered by a lack of experienced labor, product approval, and diagnostics flaws.

Due to a lack of test consistency and variations in solid-phase preparation, clinical performance is very variable. In addition, the specificity and overall accuracy of tests can also be low due to the engineering of these methods to achieve high clinical sensitivity.

This research report on the North America Antinuclear Antibody Test Market has been segmented and sub-segmented into the following categories.

By Disease: 

• SLE
• Rheumatoid Arthritis

By Technique:

• Immunofluorescence
• Multiplex
• ELISA

By Product:

• Software
• Systems
• Services
• Reagents
• Assay Kits

By End User:

• Hospitals
• Clinical Labs

By Country:

• U.S
• Canada
• Rest of North America

Geographically, North America is expected to lead the ANA market during the forecast period. An aging population that is more prone to illnesses with a deteriorating immune system contributes to the region's dominance. This results in a greater need for early diagnosis and effective treatment. 

The Centres for Disease Control and Prevention (CDC) report that GBS can affect people. However, it is becoming increasingly common in seniors, resulting in increased demand due to the country's aging population. Factors like this are driving the market in North America during the forecasted period.

During the estimated period, the United States Antinuclear Antibody Test Market is expected to dominate the North American market for Antinuclear Antibody Tests. According to a report published by the Foundation for Peripheral Neuropathy, Guillain-Barre Syndrome (GBS) impacted 3,000-6,000 people in the United States each year in 2019. The number of people insured by medical insurance in the United States is also increasing, propelling the industry in this region. The presence of prominent companies in the United States, such as Alere Inc., Antibodies Inc., Bio-Rad Laboratories, and others, is likely to fuel market growth, providing a significant revenue share and boosting the ANA market's revenue throughout the forecast period.

The Canada Antinuclear Antibody Test Market is predicted to reach a decent CAGR during the forecasted period.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Antinuclear Antibody Test Market profiled in this report are Zeus Scientific Inc., Inova Diagnostics, Immuno Concepts, Euroimmun AG, Antibodies Inc., Thermo Fisher Scientific inc., Trinity Biotech plc, ERBA Diagnostics Inc., Bio-Rad Laboratories Inc., and Alere Inc.,